User:Mr. Ibrahem/Vibegron

Vibegron, sold under the brand name Gemtesa, is a medication used to treat overactive bladder. It is used to improve the symptoms of urinary incontinence, urgency, and urinary frequency. It is taken by mouth.

Common side effects include headache, urinary tract infection, diarrhea, nausea, and upper respiratory tract infection. Other side effects may include urinary retention. Use is not recommended in people with severe kidney or liver problems. Safety in pregancy is unclear. It is a selective beta3 adrenergic receptor agonist.

Vibegron was approved for medical use in Japan in 2018 and the United States in 2020. It is not approved in the United Kingdom or Europe as of 2022. In the United States it costs about 460 USD per month as of 2022.